A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

PURPOSE: To establish recommended phase II dose (RP2D) in phase I and evaluate safety and efficacy of abivertinib in patients with EGFR Thr790Met point mutation (T790M)-positive((+)) non–small cell lung cancer (NSCLC) with disease progression from prior EGFR inhibitors in phase II. PATIENTS AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Qing, Wu, Lin, Hu, Pei, An, Tongtong, Zhou, Jianying, Zhang, Li, Liu, Xiao-Qing, Luo, Feng, Zheng, Xin, Cheng, Ying, Yang, Nong, Li, Junling, Feng, Jifeng, Han, Baohui, Song, Yong, Wang, Kai, Fang, Jian, Zhao, Hong, Shu, Yongqian, Lin, Xiao-Yan, Chen, Zhihong, Gan, Bin, Xu, Wan-Hong, Tang, Wei, Zhang, Xiaoying, Yang, Jin-Ji, Xu, Xiao, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365372/
https://www.ncbi.nlm.nih.gov/pubmed/34740925
http://dx.doi.org/10.1158/1078-0432.CCR-21-2595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365372/
https://www.ncbi.nlm.nih.gov/pubmed/34740925
http://dx.doi.org/10.1158/1078-0432.CCR-21-2595

Ejemplares similares